Back to top
more

2seventy bio, Inc. (TSVT)

(Delayed Data from NSDQ)

$4.40 USD

4.40
172,118

+0.06 (1.38%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $4.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ekta Bagri headshot

Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?

BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.

Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?

Castle Biosciences (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study

2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 17.14% and 21.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?

Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.

Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know

2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

Bristol Myers (BMY) delivered earnings and revenue surprises of 26.22% and 5.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?

Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.

Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid

A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -12.50% and 4.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.

FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.

Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion

Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.

Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.

Should You Buy 2seventy bio (TSVT) Ahead of Earnings?

2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC

Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.

Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal

Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.